HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, No. 5, May 2016 – Healthcare Systems & Policies in Asia       » Understanding Healthcare Policies in the Philippines: Cancer Care       » Young Innovators under 35       » Healthcare Cost Effectiveness in Singapore       » ASLAN Pharmaceuticals Opens China Office       » A Journey Inside the Human Body       » Treatment Brings New Hope for Patients Suffering From Fatal Lung Disease      
BIOBOARD - INDIA
Biocon receives marketing authorization for novel biologic itolizumab for psoriasis
Biocon, Asia's premier biotechnology company received marketing authorization from the Drugs Controller General of India (DCGI) for its novel biologic itolizumab, anti-CD6 molecule, for the treatment of chronic plaque psoriasis.

Itolizumab, is a first in class therapy with a unique Mechanism of Action (MOA) and an excellent safety profile as indicated during the 52 week Phase III multi-centric clinical study conducted in India. It is the second novel biologic developed by Biocon at Asia's largest biotech hub in Bangalore.

This approval paves the way for the launch of Biocon's Alzumab TM in India, later during 2013. Alzumab TM is a differentiated biologic drug with a superior safety profile compared to other approved biologic therapies given its very low opportunistic infection rates. A novel biologic indicated for the treatment of Moderate-to-Severe Psoriasis, Alzumab TM will be marketed by Biocon's Immunotherapy Division. Alzumab TM, will be manufactured and formulated as an infusion drug at Biocon's biopharma manufacturing facility at Biocon Park, Bangalore.

Commenting on this development Ms. Kiran Mazumdar-Shaw, Chairman and Managing Director, Biocon said, "We are very excited to receive this marketing authorization for Itolizumab from DCGI which will enable Biocon to introduce this novel, first in class biologic for the treatment of psoriasis patients in India. This is our second novel biologic that we have developed in India, BioMab EGFR, an anti-cancer monoclonal antibody, being the first. This approval paves the way for us to extend clinical development for other indications like rheumatoid arthritis, multiple sclerosis and vitiligo. We also intend to file a US IND shortly to enable us to embark on a global clinical development plan. This is a defining moment for Biocon as it reaches a significant milestone in its mission of delivering affordable innovation to patients worldwide."

Alzumab (TM) is expected to provide a safe and effective treatment option for psoriasis, a socially debilitating disease affecting 2-3 % of Indian population. The global psoriasis market size is estimated to cross $8 billion by 2016.

Itolizumab has shown promising preclinical and clinical efficacy in other auto immune diseases like rheumatoid arthritis and multiple sclerosis. The company aims to file a US IND in 2013 to facilitate global clinical trials in psoriasis, rheumatoid arthritis and other indications as a subcutaneous formulation. Biocon plans to develop this molecule with a global partner for various markets across the world.

Click here for the complete issue.

NEWS CRUNCH  
news World Immunisation Week 2016
news IoT Asia 2016 Delivers Actionable Solutions for a Sustainable IoT Ecosystem in Asia
news Lite-On presents a new Biomedical Research and Development Centre in Singapore
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  
APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Leading-Edge ONCOLOGY
May:
Healthcare Systems & Policies in Asia
June:
Medical Devices and Digital Health Technology
July:
Water Technology
August:
Guest Editorial - Antibody Informatics In Japan
September:
Infectious Diseases
October:
Medical Tourism
November:
Biomedical Imaging Technology
December:
Food Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim/td>
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy